Skip to main content
OpenTrials
Completed

NCT Number: NCT02714998

The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy

The investigators aimed to investigate the effects of salpingectomy and Methotrexate administration on ovarian reserve in ectopic pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ectopic Pregnancy Female Urogenital Diseases and Pregnancy Complications Genital Diseases Infertility Pregnancy Complications Pregnancy, Ectopic Urogenital Diseases

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Ege University School of Medicine Department of Obstetrics and Gynecology

Izmir, 35100, Turkey (Türkiye)

About this study

In this study, the effects of unilateral laparoscopic salpingectomy and single dose of systemic Methotrexate administration on ovarian reserve in patients diagnosed with ectopic pregnancy were investigated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ectopic pregnancy diagnosis

Exclusion criteria

  • history of endometriosis, ovarian surgery, systemic chemotherapy, ART treatment.
  • patients treated with multiple doses of methotrexate or different surgical procedure (salpingostomy, milking)

Treatment and study plan

methotrexate

Drug

single dose systemic methotrexate administration (50 mg/m2)

Other names: Mtx

Salpingectomy

Procedure

Laparoscopic unilateral salpingectomy

Primary outcomes

  1. Ovarian reserve assessment by measuring AMH level.

    Time frame: 1-3 months

    Ovarian reserve were assessed before and after treatment by measuring AMH levels.

Secondary outcomes

  1. Number of participants with treatment related adverse effect on fertility.

    Time frame: 2 years of follow up after treatment

    Rates of term delivery, spontaneous abortion, recurrent ectopic pregnancy and ongoing pregnancy for each group of patients were calculated during 2 years of follow up period.

Sponsors and collaborators

Lead sponsor

Ege University

Other

Registry information

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Mar 22, 2016
Registry last updated
Mar 22, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.